Rabies is a viral disease that causes severe neurological manifestations both in humans and mammals. Although inactivated and/or attenuated vaccines have been developed and widely used around the world, there are still concerns with regard to their safety, efficacy, and costs. As demand has grown for a new rabies vaccine, we have developed a new vesicular stomatitis viruses (VSVs) based rabies vaccine that replaces glycoproteins with rabies virus (RABV) glycoprotein (GP), or so-called VSV/RABV-GP. The generation of VSV/RABV-GP was evaluated with GP-specific antibodies and reduced transduction with GP-specific neutralizing antibodies. Mice immunized with VSV/RABV-GP produced higher levels of both IgM and IgG antibodies compared to inactivated RABV. The secretion profiles of IgG1 and IgG2a production suggested that VSV/RAVB-GP induces the T helper cell type-2 immune bias. In addition, VSV/RAVB-GP immunization produced a neutralizing antibody of 103.37 IU/mL. Our results confirm that VSV/RABV-GP could be a new potential vaccination platform for RABV.